The contemporary face of bipolar illness: Complex diagnostic and therapeutic challenges

CNS Spectrums

Volumn 13, Issue 9, 2008, Pages 763-779

  Fountoulakis, Konstantinos N ^a,b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CENTRAL STIMULANT AGENT; CHLORPROMAZINE; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; HALOPERIDOL; INOSITOL; LAMOTRIGINE; LITHIUM; LORAZEPAM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TOPIRAMATE; TRANQUILIZER; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

ADD ON THERAPY; ALCOHOLISM; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BREAST CANCER; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CYCLOTHYMIA; DELUSION; DIABETES MELLITUS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYNDROME; HAIR LOSS; HIGH RISK PATIENT; HUMAN; HYPERPROLACTINEMIA; HYPOMANIA; HYPOTHYROIDISM; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR DEPRESSION; MEMORY DISORDER; MENTAL STRESS; METABOLIC SYNDROME X; MONOTHERAPY; NEUROPSYCHOLOGICAL TEST; OVARY POLYCYSTIC DISEASE; PARANOIA; PERSONALITY DISORDER; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; PSYCHOSOCIAL DISORDER; PSYCHOTHERAPY; RAPID CYCLING BIPOLAR DISORDER; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SEDATION; SIDE EFFECT; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; SUBSTANCE ABUSE; SUICIDAL IDEATION; SUICIDE ATTEMPT; SYMPTOM; TARDIVE DYSKINESIA; TEMPERAMENT; TERATOGENICITY; TRANSCRANIAL MAGNETIC STIMULATION; TREMOR; WEIGHT GAIN;

EID: 54349117963     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900013894     Document Type: Review

References (240)

1. Kraepelin E. Manic-Depressive Insanity and Paranoia. Manchester, NH: Ayer Company Publishers; 1921.
2. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord. 1998;50:143-151.
3. Judd LL, Akinkal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord. 2003;73:123-131.
4. Tohen M, Waternaux CM, Tsuang MT. Outcome in Mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry. 1990;47:1106-1111.
5. Diagnostic and Statistical Manuals of Mental Disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.
6. Kennedy N, Boydell J, Kalidindi S, et al. Gender differences in incidence and age at onset of mania and bipolar disorder over a 35-year period in Camberwell, England. Am J Psychiatry. 2005;162:257-262.
7. Akiskal H. Mood disorders. In: Sadock B, Sadock V, eds. Comprehensive Textbook of Psychiatry. vol 1. Philadelphia Penn: Lippincott Williams & Wilkins; 2000:1338-1377.
8. Akiskal HS, Pinto O. The evolving bipolar spectrum. Prototypes I, II, III, and IV. Psychiatr Clin North Am. 1999;22:517-34, vii.
9. Hantouche EG, Akiskal HS, Lancrenon S, et al. Systematic clinical methodology for validating bipolar-II disorder: data in mid-stream from a French national multi-site study (EPIDEP). J Affect Disord. 1998;50:163-173.
10. Manning JS, Haykal RF, Connor PD, Akiskal HS. On the nature of depressive and anxious states in a family practice setting: the high prevalence of bipolar II and related disorders in a cohort followed longitudinally. Compr Psychiatry. 1997;38:102-108.
11. Angst J, Sellaro R, Stassen HH, Gamma A. Diagnostic conversion from depression to bipolar disorders: results of a long-term prospective study of hospital admissions. J Affect Disord. 2005;84:149-157.
12. Mitchell PB, Malhi GS. Bipolar depression: phenomenological overview and clinical characteristics. Bipolar Disord. 2004;6:530-539.
13. Judd LL, Akiskal HS, Schettler PJ, et al. The ong-term natural history of the meekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59:530-537.
14. Perugi G, Akiskal HS, Lattanzi L, et al. The high prevalence of "soft" bipolar (II) features in atypical depression. Compr Psychiatry. 1998;39:63-71.
15. Mitchell PB, Goodwin GM, Johnson GF, Hirschfeld RM. Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disord. 2008;10(pt 2):144-152.
16. Akiskal HS, Benazzi F. Continuous distribution of atypical depressive symptoms between major depressive and bipolar II disorders: dose-response relationship with bipolar family history. Psychopathology. 2008;41:39-42.
17. Geller B, Fox LW, Clark KA. Rate and predictors of prepubertal bipolarity during follow-up 6- to 12-year-old depressed children. J Am Acad Child Adolesc Psychiatry. 1994;33:461-468.
18. Thase ME. Recognition and diagnosis of atypical depression. J Clin Psychiatry. 2007;68(suppl 8):11-16.
19. Fountoulakis KN, Iacovides A, Nimatoudis I, Kaprinis G, Ierodiakonou C. Comparison of the diagnosis of melancholic and atypical features according to DSM-IV and somatic syndrome according to ICD-10 in patients suffering from major depression. Eur Psychiatry. 1999;14:426-433.
20. Akiskal HS, Benazzi F. Atypical depression: a variant of bipolar II or a bridge between unipolar and bipolar II? J Affect Disorders. 2005;84:209-217.
21. Parker G, Parker K, Mitchell P, Wilhelm K. Atypical depression: Australian and US studies in accord. Curr Opin Psychiatry. 2005;18:1-5.
22. Akiskal HS, Benazzi F. Validating Kraepelin's two types of depressive mixed states: "depression with flight of ideas" and "excited depression." World J Biol Psychiatry. 2004; 5:107-113.
23. McGlashan TH. The Chestnut Lodge follow-up stady III. Long-term outcome of borderline personalities. Arch Gen Psychiatry. 1986;43:20-30.
24. Akiskal HS, Hantouche EG, Bourgeois ML, et al. Gender, temperament, and the clinical picture in dysphoric mixed mania: findings from a French national study (EPIMAN). J Affect Disord. 1998;50:175-186.
25. Akiskal HS. The prevalent clinical spectram of bipolar disorders: beyond DSM-IV. J Clin Psychopharmacol. 1996;16(suppl 1):4S-14S.
26. Ng B, Camacho A, Lara DR, Branstein MG, Pinto OC, Akiskal HS. A case series on the hypothesized connection between dementia and bipolar spectrum disorders: bipolar type VI? J Affect Disord. 2008;107:307-315.
27. Maj M, Pirozz R, Magliano L, Bartoli L. Agitated depression in bipolar I disorder: prevalence, phenomenology, and outcome. Am J Psychiatry. 2003;160:2134-2140.
28. Sato T, Bottlender R, Kleindienst N, Moller HJ. Irritable psychomotor elation in depressed inpatients: a factor validation of mixed depression. J Affect Disord. 2005;84:187-196.
29. Altshuler LL, Suppes T, Black DO, et al. Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Am J Psychiatry. 2006;163:313-315.
30. Serretti A, Artioli P, Zanardi R, et al. Genetic features of antidepressant induced mania and hypomania in bipolar disorder. Psychopharmacology (Berl). 2004;174:504-511.
31. Wada K, Sasaki T, Jitsuiki H, et al. Manic/hypomanic switch during acute antidepressant treatment for uniplolar depression. J Clin Psychopharmacol. 2006;26:512-515
32. Tyrer P, Mitchard S, Methuen C, Ranger M. Treatment rejecting and treatment seeking personality disorders: Type R and Type S. J Personal Disord. 2003;17:263-268.
33. Fountoulakis KN, Kaprinis GS. Personality disorders: new data versus old concepts. Curr Opin Psychiatry. 2006;19:90-94.
34. Akiskal H, Akiskal K. Epilogue. The renaissance of the ancient concept of temperament (with a focus on affective temperaments), In: Maj M, Akiskal HS, Mezzich JE, Okasha A, eds. Personality Disorders. Hoboken, NJ: John Wiley & Sons, Inc.; 2005;479-500.
35. Cloninger C, Svrakic D, Bayon C, Przybeck T. Measurement of psychopathology as variants of personality. In: Cloninger CR, ed. Personality and Psychopathology (American Psychopathological Association Series). 1st ed. Washington, DC: American Psychiatric Publishing, Inc.; 1999:33-65.
36. Costa PT Jr, McCrae RR. Personality disorders and the five-factor model of personality. J Personal Disord. 1990;4:362-371.
37. Tellegen A, Grove W, Waller N. Inventory of Personality Characteristics #7 (IPC7). Minneapolis, Minn: University of Minnesota Department of Psychology; 1991.
38. Cattel RB. Handbook for the Sixteen Personality Factor Questionnaire. Champaign, III: Institute for Personality and Ability Testing; 1970.
39. Akiskal HS, Akiskal KK, Haykal RF, Manning JS, Connor PD. TEMPS-A: progress towards validation of a self-rated clinical version of the Temperament Evaluation of the Memphis, Pisa, Paris, and San Diego Autoquestionnaire. J Affect Disord. 2005;85:3-16.
40. Cohen P. Personality development in childhood: old and new findings. In: Cloninger CR, ed. Personality and Psychopathology(American Psychopathological Association Series). 1st ed. Washington, DC: American Psychiatric Publishing, Inc.; 1999;101-127.
41. Maremmani I, Akiskal HS, Signoretta S, Liguori A, Perugi G, Cloninger CR. The relationship of Kraepelian affective temperaments (as measured by TEMPS-I) to the tridimensional personality questionnaire (TPQ). J Affect Disord. 2005;85:17-27.
42. Bolton S, Gunderson J. Distinguishing borderline personality disorder from bipolar disorder: differential diagnosis and implications. Am J Psychiatry. 1996;153:1202-1207.
43. Parnas J, Licht D, Bovet P. Cluster A personality disorders: a review. In: Maj M, Akiskal HS, Mezzich JE, Okasha A, eds. Personality Disorders. Hoboken, NJ: John Wiley & Sons, Inc.; 2005:1-74.
44. Zanarini M, Frankenburg F, Vujanovic A, Hennen J, Reich D, Silk K. Axis II comorbidity of borderline personality disorder: description of 6-year course and prediction to time-to-remission. Acta Psychiatr Scand. 2004;110:416-420.
45. Stone M. Long-term outcome in personality disorders. Br J Psychiatry. 1993;162;299-313.
46. Grilo CM, Skodol AE, Ganderson JG, et al. Longitudinal diagnostic efficiency of DSM-IV criteria for obsessive-compulsive personality disorder: a 2-year prospective study. Acta Psychiatr Scand. 2005;110:64-68.
47. McGlashan T, Grilo C, Sanislow C, et al. Two-year prevalence and stability of individual DSM-IV criteria for schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders: toward a hybrid model of axis II disorders. Am J Psychiatry. 2005;162:883-889.
48. Akiskal HS, Djenderedjian AM, Rosenthal RH, Khani MK. Cyclothymic disorder: validating criteria for inclusion in the bipolar affective group. Am J Psychiatry. 1977;134:1227-1233.
49. Judd LL, Schettler PJ, Akiskal HS, et al. Residual symptom recovery from major affective episodes in bipolar diosrders and rapid episode relapse/ recurrence. Arch Gen Psychiatry. 2008;65:386-394.
50. Bauer MS, Calabrese J, Dunner DL, et al. Multisite data reanalysis of the validity of rapid cycling as a course modifier for bipolar disorder in DSM-IV. Am J Psychiatry. 1994;151:506-515.
51. Winokur G, Turvey C, Akiskal H, et al. Alcoholism and drug abuse in three groups - bipolar I, unipolars and their acquaintances. J Affect Disord. 1998;50:81-89.
52. Akiskal HS, Benazzi F. Family history validation of the bipolar nature of depressive mixed states. J Affect Disord. 2003;73:113-122.
53. Brieger P, Roettig S, Ehrt U, Wenzel A, Bloink R, Marneros A. TEMPS-a scale in 'mixed' and 'pure' manic episodeo: new data and methodological considerations on the relevance of joint anxious-depressive temperament traits. J Affect Disord. 2003;73:99-104.
54. Oedegaard KJ, Neckelmann D, Fasmer OB. Type A behaviour differentiates bipolar II from unipolar depressed patients. J Affect Disord. 2006;90:7-13.
55. Engstrom C, Brandstrom S, Sigvardsson S, Cloninger CR, Nylander PO. Bipolar disorder. III: harm avoidance a risk factor for suicide attempts. Bipolar Disord. 2004;6:130-138.
56. Engstrom C, Brandstrom S, Sigvardsson S, Cloninger R, Nylander PO. Bipolar disoder: I. Temperament and character. J Affect Disord. 2004;82:131-134.
57. Perugi G, Toni C, Passino MC, Akiskal KK, Kaprinis S, Akiskal HS. Bulimia nervosa in atypical depression: the mediating role of cyclothymic temperament. J Affect Disord. 2006;92:91-97.
58. Goldberg JF, Harrow M, Grossman LS. Course and outcome in bipolar affective disorder: a longitudinal follow-up study. Am J Psychiatry. 1995;152:379-384.
59. Goldberg JF, Harrow M, Groosman LS. Recurrent affective syndromes in bipolar and unipolar mood disorders at follow-up. Br J Psychiatry. 1995;166:382-385.
60. Keck PE Jr, McElroy SL, Strakowski SM, et al. Twelve-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry. 1998;155:646-652.
61. Strakowski SM, Keck PE Jr, McElroy SL, et al. Twelve-month outcome after a first hospitalization for affective psychosis. Arch Gen Psychiatry. 1998;55:49-55.
62. Dean BB, Gerner D, Gerner RH. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Curr Med Res Opin. 2004;20:139-154.
63. Martinez-Aran A, Vieta E, Torrent C, et al. Functional outcome in bipolar disorder: the role of clinical and cognitive factors. Bipolar Disord. 2007;9:103-113.
64. Mur M, Portella MJ, Martinez-Aran A, Pifarre J, Vieta E. Persistent neuropsychological deficit in euthymic bipolar patients: executive function as a core deficit. J Clin Psychiatry. 2007;68:1078-1086.
65. Daban C, Martinez-Aran A, Torrent C, et al. Specificity of cognitive deficits in bipolar disorder versus schizophrenia. A systematic review. Psychother Psychosom. 2006;75:72-84.
66. Altshuler LL, Ventura J, van Gorp WG, Green MF, Theberge DC, Mints J. Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects. Biol Psychiatry. 2004;56:560-569.
67. Dixon T, Kravariti E, Frith C, Murray RM, McGuire PK. Effect of symptoms on executive function in bipolar illness. Psychol Med. 2004;34:811-821.
68. Malhi GS, Ivanovski B, Szekeres V, Olley A. Bipolar disorder: it's all in your mind? The neuropsychological profile of a biological disorder. Can J Psychiatry. 2004;49:813-819.
69. Torrent C, Martinez-Aran A, Daban C, et al. Cognitive impairment in bipolar II disorder. Br J Psychiatry. 2006;189:254-259.
70. Taberes-Seisdedos R, Balanza-Martinez V, Sanches-Moreno J, et al. Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. J Affect Disord. 2008;109:286-299.
71. Torrent C, Martinez-Aran A, Amann B, et al. Cognitive impairment in schizoaffective disorder: a cnmparison with non-psychotic bipolar and healthy subjects. Acta Psychiatr Scand. 2007;116:453-460.
72. Selva G, Salazar J, Balanza-Martinez V, et al. Bipolar I patients with and without a history of psychotic symptoms: do they differ in their cognitive functionng? J Psychiatr Res. 2007;41:265-272.
73. Martinez-Aran A, Torrent C, Tabares-Seisdedos R, et al. Neurocognitive impairment in bipolar patients with and without history of psychosis. J Clin Psychiatry. 2008;69:233-239.
74. Jamison KR. Suicide and bipolar disorder. J Clin Psychiatry. 2000;61(suppl 9):47-51.
75. Valtonen HM, Suominen K, Mantere O, Leppamaki S, Arvilommi P, Isometsa ET. Prospective study of risk factors for attempted suicide among patients with bipolar disorder. Bipolar Disord. 2006:8(pt 2):576-585.
76. Baldessarini RJ, Pompili M, Tondo L. Suicide in bipolar disorder: risks and management. CNS Spectr. 2006;11:465-471.
77. Balazs J, Benazzi F, Rihmer Z, Rihmer A, Akiskal KK, Akiskal HS. The close link between suicide attempts and mixed (bipolar) depression: implications for suicide prevention. J Affect Disord. 2006;91:133-138.
78. Isometsa ET, Henriksson MM, Aro HM, Heikkinen ME, Kuoppasalmi KI, Lonnqvist JK. Suicide in major depression. Am J Psychiatry. 1994;151(4):530-536.
79. Rihmer Z, Akiskal H. Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries. J Affect Disord. 2006;94:3-13.
80. Akiskal HS, Benazzi F, Perugi G, Rihmer Z. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. J Affect Disord. 2005;85:245-258.
81. Rihmer Z. Suicide risk in mood disorders. Curr Opin Psychiatry. 2007;20:17-22.
82. Maser JD, Akiskal HS, Schettler P, et al. Can temperament identify affectively ill patients who engage in lethal or near-lethal suicidal behavior? A 14-year prospective study. Suicide Life Threat Behav. 2002;32:10-32.
83. Oquendo MA, Currier D, Mann JJ. Prospective studies of suicidal behavior in major depressive and bipolar disorders: what is the evidence for predictive risk factors? Acta Psychiatr Scand. 2006;114:151-158.
84. Simon NM, Pollack MH, Ostacher MJ, et al. Understanding the link between anxiety symptoms and suicidal ideation and behaviors in outpatients with bipolar disorder. J Affect Disord. 2007;97:91-99.
85. Frank E, Cyranowski JM, Rucci P, et al. Clinical significance of lifetime panic spectrum symptoms in the treatment of patients with bipolar I disorder. Arch Gen Psychiatry. 2002;59:905-911.
86. Oquendo MA, Bongiovi-Garcia ME, Galfalvy H, et al. Sex differences in clinical predictors of suicidal acts after major depression: a prospective study. Am J Psychiatry. 2007;164:134-141.
87. Comtois KA, Russo JE, Roy-Byrne P, Ries RK. Clinicians' assessments of bipolar disorder and substance abuse as predictors of suicidal behavior in acutely hospitalized psychiatric inpatients. Biol Psychiatry. 2004;56:757-763.
88. Cavazzoni P, Grof P, Duffy A, et al. Heterogeneity of the risk of suicidal behavior in bipolar-spectrum disorders. Bipolar Disord. 2007;9:377-385.
89. Hawton K, Sutton L, Haw C, Sinclair J, Harriss L. Suicide and attempted suicide in bipolar disorder: a systematic review of risk factors. J Clin Psychiatry. 2005;66:693-704.
90. Williams JM, Crane C, Barnhofer T, Van der Does AJ, Segal ZV. Recurrence of suicidal ideation across depressive episodes. J Affect Disord. 2006;91:189-194.
91. Valtonen H, Suominen K, Mantere O, Leppamaki S, Arvilommi P, Isometsa ET. Suicidal ideation and attempts in bipolar I and II disorders. J Clin Psychiatry. 2005;66:1456-1462.
92. Rihmer Z, Belso N, Kiss K. Strategies for suicide prevention. Curr Opin Psychiatry. 2002;15:83-87.
93. Isometsa E, Henriksson M, Aro H, Heikkinen M, Kuoppasalmi K, Lonnqvist J. Suicide in psychotic major depression. J Affect Disord. 1994;31:187-191.
94. Leverich GS, Altshuler LL, Frye MA, et al. Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. J Clin Psychiatry. 2003;64:506-515.
95. Leverich GS, McElroy SL, Suppes T, et al. Early physical and sexual abuse associated with an adverse course of bipolar illness. Biol Psychiatry. 2002;51:288-297.
96. Luoma JB, Martin CE, Pearson JL. Contact with mental health and primary care providers before suicide: a review of the evidence. Am J Psychiatry. 2002;159:909-916.
97. Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry. 2005;162:1805-1819.
98. Sachs GS, Thase ME, Otto MW, et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry. 2003;53:1028-1042.
99. Bauer MS, Wisniewski SR, Marangell LB, et al. Are antidepressants associated with new-onset suicidality in bipolar disorder? A prospective study of participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). JJ Clin Psychiatry. 2006;67:48-55.
100. Fountoulakis KN, Grunze H, Panagiotidis P, Kaprinis G. Treatment of bipolar depression: an update. J Affect Disord. 2007;109:21-34.
101. Fountoulakis KN, Magiria S, Siamouli M, et al. A seven-year follow-up of an extremely refractory bipolar I patient. CNS Spectr. 2007;12:733-734.
102. Fountoulakis KN, Vieta E, Sanchez-Moreno J, Kaprinis SG, Goikolea JM, Kaprinis GS. Treatment guidelines for bipolar disorder: a critical review. J Affect Disord. 2005;86:1-10.
103. Fountoulakis KN, Vieta E, Siamouli M, et al. Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder. Ann Gen Psychiatry. 2007;6:27.
104. Vieta E, Carne X. The use of placebo in clinical trials on bipolar disorder: a new approach for an old debate. Psychother Psychosom. 2005;74:10-16.
105. Post R, Leverich G, Altshuler L, Mikalauskas K. Lithium-discontinuation-induced refractoriness: preliminary observations. Am J Psychiatry. 1992;149:1727.
106. Expert consensus guidelines are released fnr the treatment of bipolar disorder. Consensus Development Conferences. Am Fam Physician. 1997;55:1447-1449.
107. AACAP: AACAP official action. Practice parameters for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 1997;36:138-157.
108. Allen MH, Currier GW, Hughes DH, Reyes-Harde M, Docherty JP. The Expert Consensus Guideline Series. Treatment of behavioral emergencies. Postgrad Med. 2001;(spec no):1-88.
109. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry. 1994,151:1-36.
110. American Psychiatric Association releases treatment guideline for bipolar disease. Am Fam Physician. 1995;51:1605-1606.
111. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder [revision]. Am J Psychiatry. 2002;159:1-50.
112. Barreira P, Duckworth K, Goff D, Flannery RB Jr. Clinical practice guidelines: the Massachusetts experience in psychiatry. Harv Rev Psychiatry. 1999;7:230-232.
113. Dennehy EB. Guidelines for treatment of bipolar disorder. Curr Psychiatry Rep. 2000;2.316-321.
114. Gilbert DA, Altshuler KZ, Rago WV, et al. Texas Medication Algorithm Project: definitions, rationale, and methods to develop medication algorithms. J Clin Psychiatry. 1998;59:345-351.
115. Goldberg JF. Treatment guidelines: current and future management of bipolar disorder. J Clin Psychiatry. 2000;61(suppl 13):12-18.
116. Goodwin G, Bourgeois M, Conti L. Treatment of bipolar depressive mood disorders: algorithms for pharmacotherapy. Int J Psychiatry Clin Pract. 1997;1:S9-S12.
117. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2003;17:149-173.
118. Grunze H, Kasper S, Goodwin G, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. World J Biol Psychiatry. 2002;3:115-124.
119. Grunze H, Kasper S, Goodwin G, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World J Biol Psychiatry. 2003;4:5-13.
120. Jobson K. International Psychopharmacology Algorithm Project: algorithms in psychopharmacology. Int J Psychiatry Clin Pract. 1997;1:S3-S8.
121. Kusumakar V, Yatham L, Parikh S. Bipolar disorder: a summary of clinical issues and treatment options. Halifax, Canada: CANMAT Monograph; 1997.
122. Licht RW,Vestergaard P,Kessing LV,Larsen JK,Thomsen PH. Psychopharmacological treatment wits lithium and antiepileptic drugs: suggested guidelines from tne Danish Psychiatric Association and thee Child and Adolescent Psychiatric Association in Denmark. Acta Psychiatr Scand Suppl. 2003;108:1-22.
123. McClellan J, Werry J. Practice parameters for the assessment and treatment of children and adolescents with bipolar disorder. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 1997;36:157S-176S.
124. Montgomery DB. ECNP Consensus Meeting March 2000 Nice: guidelines for investigating efficacy in bipolar disorder. European College of Neuropsychopharmacology. Eur Neuropsychopharmacol. 2001;11:79-88.
125. Rush AJ, Crismon ML, Kashner TM, et al. Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. J Clin Psychiatry. 2003;64:357-369.
126. Rush AJ, Rago WV, Crismon ML, et al. Medication treatment for the severely and persistently mentally ill: the Texas Medication Algorithm Project. J Clin Psychiatry. 1999;60:284-291.
127. Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP. The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. Postgrad Med. 2000;spec no:1-104.
128. Suppes T, Calabrese J, Mitchell P, Pazzaglia P, Potter W, Zarin D. Algorithms for the treatment of bipolar manic-depressive illness. Psychopharmacol Bull. 1995;31:469-474.
129. Suppes T, Dennehy EB, Swann AC, et al. Report of the Texas Consensus Conference Panel on medication treatment of bipolar disorder 2000. J Clin Psychiatry. 2002;63:288-299.
130. Suppes T, Rush AJ, Dennehy EB, et al. Texas Medication Algorithm Project, phase 3(TMAP-3): clinical results for patients with a history of mania. J Clin Psychiatry. 2003;64:370-382.
131. Suppes T, Swann AC, Dennehy EB, et al. Texas Medication Algorithm Project: development and feasibility testing of a treatment algorithm for patients with bipolar disorser. J Clin Psychiatry. 2001;62:439-447.
132. O'Dowd A. NICE issues new guidance to improve the treatment of bipolar disorder. BMJ. 2006;333:220.
133. Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management patients with bipolar disorder: consensus and controversies. Bipolar Disord. 2005;7:5-69.
134. Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord. 2006; 8:721-739.
135. Grunze H, Kasper S, Goodwin G, Bowden C, Moller HJ. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. World J Biol Psychiatry. 2004;5:120-135.
136. Frances A, Docherty J, Kahn D. The Expert Consensus Guideline Series: treatment of bipolar disorder. J Clin Psychiatry. 1996;57:1-88.
137. Bauer MS, Callahan AM, Jampala C, et al. Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs. J Clin Psychiatry. 1999;60:9-21.
138. Hirschfeld RMA. Guideline Watch for the Practice Guideline for the Treatment of Patients With Bipolar Disorder. 2nd ed. Arlington, Va: American Psychiatric Association; 2005.
139. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA. 1994;271:918-924.
140. Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry. 2005;66:111-121.
141. Kushner SF, Khan A, Lane R, Olson WH. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord. 2006;8:15-27.
142. Keck PE Jr, Sanchez R, Torbeyns A, Marcus R, McQuade R, Forbes A. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized placebo- and lithium-controlled study (Study CN138-135). Paper presented at: Annual Meeting of the American Psychiatric Association; May 19-24, 2007. San Diego, Calif.
143. Young AH, McElroy H, Chang W, Olausson B, Paulsson B, Brecher M. A double-blind, placebo-controlled study with acute and continuation phase of quetiapine in adults with bipolar depression (EMBOLDEN i). Paper presented at Biennial Conference of the International Society for Bipolar Disorders; January 27-28, 2008. Delhi, India.
144. Kane JM, Quitkin FM, Ritkin A, Ramos-Lorenzi JR, Nayak DD, Howard A. Lithium carbonate and imipramine in the prophylaxis unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Arch Gen Psychiatry. 1982;39:1065-1069.
145. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry. 2000;57:481-489.
146. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60:392-400.
147. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;64:1013-1024.
148. Calabrese JR, Goldberg JF, Ketter TA, et al. Recurrence in bipolar I disorder: a post hoc analysis excluding relapses in two double-blind maintenance studies. Biol PPsychiatry. 2006;59:1061-1064.
149. Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry. 2004;65:432-441.
150. Goodwin GM. Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective dsorder. Br J Psychiatry. 1994;64:149-152.
151. Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord. 2006;8:625-639.
152. Gonzalez-Pinto A, Mosquera F, Alonso M, et al. Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord. 2006;8:618-624.
153. Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003;160:1651-1658.
154. Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol. 2006;20:536-546.
155. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry. 1999;156:702-709.
156. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry. 2000;57:841-849.
157. Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment adolescents with bipolar mania. Am J Psychiatry. 2007;164:1547-1556.
158. McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J. Quetiapine or haloperidol as monotherapy for bipolar mania-a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol. 2005;15:573-585.
159. Gopal S, Steffens DC, Kramer ML, Olsen MK. Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy. J Clin Psychiatry. 2005;66:1016-1020.
160. Hirschfeld RM, Keck PE Jr, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry. 2004;161:1057-1065.
161. Khanna S, Vieta E, Lyons B, Grossman F, Eerdekens M, Kramer M. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry. 2005;187:229-234.
162. Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol. 2005;15:75-84.
163. Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003;160:741-748.
164. Potkin SG, Keck PE Jr, Segal S, Ice K, English P. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol. 2005;25:301-310.
165. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depreooion. Arch Gen Psychiatry. 2003;60:1079-1088.
166. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162:1351-1360.
167. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26:600-609.
168. McQuade RD, Sanchez R, Marcus R, et al. Aripiprazole for relapse prevention in bipolar disorder: a 26-week placebo-controlled study. Int J Neuropsychopharmacol. 2004;7:s161.
169. Keck PE Jr, Calabrese JR, McIntyre RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry. 2007;68:1480-1491.
170. Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006;163:247-256.
171. Altamura AC, Mundo E, Dell'Osso B, Tacchini G, Buoli M, Calabrese JR. Quetiapine and classical mood stabilizers in the long-term treatment of Bipolar Disorder: a 4-year follow-up naturalistic study. J Affect Disord. 2008;110:135-141.
172. Altamura AC, Salvadori D, Madaro D, Santini A, Mundo E. Efficacy and tolerability of quetiapine in the treatment of bipolar disorder: preliminary evidence from a 12-month open-label study. J Affect Disord. 2003;76:267-271.
173. Shopsin B, Gershon S, Thompson H, Collins P. Psychoactive drugs in mania. A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol. Arch Gen Psychiatry. 1975;32:34-42.
174. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003;60:1218-1226.
175. Zarate CA Jr, Tohen M. Double-blind comparison of the continued use of anti-psychotic treatment verses its discontinuation in remitted manic patients. Am J Psychiatry. 2004;161:169-171.
176. Pope HG Jr, McElroy SL, Keck PE Jr, Hudson JI. Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry. 1991;48:62-68.
177. Bowden CL, Swann AC, Calabrese JR, et al. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry. 2006;67:1501-1510.
178. Weisler RH, Kalali AH, Ketter TA. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mined episodes. J Clin Psychiatry. 2004;65:478-484.
179. Weisler RH, Hirschfeld R, Cutler AJ, et al. Extended-release carbamazepine capsules as monotherapy in bipolar disorder: pooled results from two randomised, double-blind, placebo-controlled trials. CNS Drugs. 2006;20:219-231.
180. Weisler RH, Keck PE Jr, Swann AC, Cutler AJ, Keller TA, Kalali AH. Extended-release carbamazepine capsules us monotharapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2005;66:323-330.
181. Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord. 2005;85:259-266.
182. Ghaemi SN, Gilmer WS, Goldberg JF, et al. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry. 2007;68:1840-1844.
183. Ballenger JC, Post RM. Carbamazepina in manic-depressive illness: a new treatment. Am J Psychiatry. 1980;137:782-790.
184. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM. Lamotrigine: a review of its use in bipolar disorder. Drugs. 2003;63:2029-2050.
185. Okuma T, Inanaga K, Otsuki S, et al. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology (Berl). 1981;73:95-96.
186. Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry. 2000;61:841-850.
187. Oulis P, Karapoulios E, Kouzoupis AV, et al. Oxcarbazepine as monotherapy of acute mania in insufficiently controlled type-1 diabetes mellitus: a case-report. Ann Gen Psychiatry. 2007;6:25.
188. Post RM, Altshuler LL, Frye MA, et al. Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disord. 2001;3:259-265.
189. Post RM, Altshuller LL, Leverich GS, et al. Mood Switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry. 2006;189:124-131.
190. Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry. 2006;163:232-239.
191. Bottlender R, Rudolf D, Strauss A, Moller HJ. Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. J Affect Disord. 2001;63:79-83.
192. Cohn JB, Collins G, Ashbrook E, Wernicke JF. A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol. 1989;4:313-322.
193. Amsterdam JD, Garcia-Espana F, Fawcett J, et al. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J Clin Psychopharmacol. 1998;18:435-440.
194. Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression-lack of manic induction. J Affect Disord. 2005;87:121-130.
195. Amsterdam JD, Shults J. Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study. lInt Clin Psychopharmacol. 2005;20:257-264.
196. Brown EB, McElroy SL, Keck PE Jr, et al. A 7-weak, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry. 2006;67:1025-1033.
197. Keck PE Jr, Corya SA, Altshuler LL, et al. Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. J Clin Psychiatry. 2005;66:611-616.
198. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356:1711-1722.
199. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001;158:906-912.
200. Zarate CA Jr, Singh JB, Carlson PJ, et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord. 2007;9:561-570.
201. Kulkarni J, Garland KA, Scaffidi A, et al. A pilot study of hormone modulation as a new treatment for mania in woman with bipolar affective disorder. Psychoneuroendocrinology. 2006;31:543-547.
202. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry. 2002;159:1146-1154.
203. Garfinkel PE, Stancer HC, Persad E. A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania. J Affect Disord. 1980;2:279-288.
204. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry. 2003;182:141-147.
205. Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresposive to valproate or lithium monotheraphy. Arch Gen Psychiatry. 2002;59:62-69.
206. Sachs G, Chengappa KN, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placabo-controlled study. Bipolar Disord. 2004;6:213-223.
207. Yatham LN, Paulsson B, Mullen J, Vagero AM. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol. 2004;24:599-606.
208. Klein E, Bental E, Lerer B, Belmaker RH. Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. Arch Gen Psychiatry. 1984;4:165-170.
209. Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry. 2004;184:337-345.
210. Small JG, Klapper MH, Marhenke JD, Milstein V, Woodham GC, Kellams JJ. Lithium combined with carbamazepine or haloperidol in the treatment of mania. Psychopharmacol Bull. 1995;31:265-272.
211. Lenox RH, Newhouse PA, Creelman WL, Whitaker TM. Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study. J Clin Psychiatry. 1992;5347-52.
212. Vieta E, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex as maintenance treatment for patients with bipolar I disorder: results from an international, multicenter, randomized, double-blind, parallel-group trial (Trial 126). Paper presented at: 20th Annual Congress of the European College of Neuropsychopharmocology; October 13-17, 2007; Vienna, Austria.
213. Weisler R, Dunn J, English P. Adjunctive ziprasidone for acute bipolar mania: randomized, placebo-controlled trial. Paper presented at: Annual International Forum on Mood and Anxiety Disorders; November 19-21, 2003. Monte Carlo, Monaco.
214. Schaffer A, Zuker P, Levitt A. Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. J Affect Disord. 2006;96:95-99.
215. Chou JC, Czobor P, Charles O, et al. Acute mania: haloperidol dose and augmentation with lithium or lorazepam. J Clin Psychopharmacol. 1999;19:500-505.
216. Muller-Oerlinghausen B, Retzow A, Henn FA. Giedke H, Walden J. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group. J Clin Psychopharmacol. 2000;20:195-203.
217. Del Bello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2002;41:1216-1223.
218. Gyulai L, Bowdan CL, McElroy SL, et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacol. 2003;28:1374-1382.
219. Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, Post RM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry. 1997;58:470-478.
220. Ball JR, Mitchell PB, Corry JC, Skillecorn A, Smith M, Malhi GS. A randomized controlled trial of cognitive therapy for bipolar disorder: focus on long-term change. J Clin Psychiatry. 2006;67:277-286.
221. Miklowitz DJ, Otto MW, Frank E, et al. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry. 2007;64:419-426.
222. Colom F, Vieta E, Sanchez-Moreno J, et al. Stabilizing the stabilizer: group psychoeducation enhances the stability of serum lithium levels. Bipolar Disord. 2005;7:32-36.
223. Scott J, Colom F, Vieta E. A meta-analysis of relapse rates with adjunctive psychological therapies compared to usual psychiatric treatment for bipolar disorders. Int JJ Neuropsychopharmacol. 2007;10:123-129.
224. Reinares M, Vieta E, Colom F, et al. Impact of a psychoeducational family intervention on caregivers of stabilized bipolar patients. Psychother Psychosom. 2004;73:312-319.
225. Colom F, Vieta E, Sanchez-Moreno J, et al. Psychoeducation in bipolar patients with comorbid personality disorders. Bipolar Disord. 2004;6:294-298.
226. Colom F, Vieta E, Reinares M, et al. Psychoeducation efficacy in bipolar disorders: beyond compliance enhancement. J Clin Psychiatry. 2003;64:1101-1105.
227. Colom F, Vieta E, Martinez-Aran A, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry. 2003;60:402-407.
228. Daly JJ, Prudic J, Devanand DP, et al. ECT in bipolar and unipolar depression: differences in speed of response. Bipolar Disord. 2001;3:95-104.
229. Small JG, Klapper MH, Kellams JJ, et al. Elactroconvulsive treatment compared with lithium in the management of manic states. Arch Gen Psychiatry. 1988;45:727-732.
230. Sikdar S, Kulhara P, Avasthi A, Singh H. Combined chlorpromazine and electroconvulsive therapy in mania. Br J Psychiatry. 1994;164:806-810.
231. Dolberg OT, Dannon PN, Schreiber S, Grunhaus L. Transcranial magnetic stimulation in patients with bipolar depression: a double blind, controlled study. Bipolar Disord. 2002;4:94-95.
232. Nahas Z, Kozel FA, Li X, Anderson B, George MS. Left prefrontal transcranial magnetic stimulation (TMS) treatment of depression in bipolar affective disorder: a pilot study of acute safety and efficacy. Bipolar Disord 2003;5:40-47.
233. Saba G, Rocamora JF, Kalalou K, et al. Repetitive transcranial magnetic stimulation as an add-on therapy in the treatment of mania: a case series of eight patients. Psychiatry Res. 2004;128:199-202.
234. Goldberg JF, Allen MH, Miklowitz DA, et al. Suicidal ideation and pharmacotherapy among STEP-BD patients. Psychiatr Serv. 2005;56:1534-1540.
235. Goldberg JF, Perlis RH, Ghaemi SN, et al. Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD. Am J Psychiatry. 2007;164:1348-1355.
236. Schneck CD, Miklowitz DJ, Miyahara S, et al. The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD. Am J Psychiatry. 2008.
237. Truman CJ, Goldberg JF, Ghaemi SN, et al. Self-reported history of manic/ hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Clin Psychiatry. 2007;68:1472-1479.
238. Ghaemi SN, Hsu DJ, Thase ME, Wisniewski SR, Nierenberg AA, Miyahara S, Sachs G. Pharmacological Treatment Patterns at Study Entry for the First 500 STEP-BD Participants. Psychiatr Serv. 2006;57:660-665.
239. Miklowitz DJ, Otto MW, Frank E, et al. Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trial. Am J Psychiatry. 2007;164:1340-1347.
240. Nierenberg AA, Ostacher MJ, Calabrese JR, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry. 2006;163:210-216.